Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioForm Medical Does Not Expect Any Wrinkles In Upcoming Submission

This article was originally published in The Gray Sheet

Executive Summary

BioForm Medical says it plans to submit a PMA for a new product to fill face wrinkles by the end of November
Advertisement

Related Content

FDA Approves BioForm’s Radiesse Dermal Filler For HIV, Cosmetic Indications
FDA Approves BioForm’s Radiesse Dermal Filler For HIV, Cosmetic Indications
Radiesse Dermal Filler Gets Two Approval Recommendations From FDA Panel
Radiesse Dermal Filler Gets Two Approval Recommendations From FDA Panel
BioForm Dermal Filler PMAs Up For FDA Panel Review In August
New Bulking Agent To Be Marketed By “Major” Urology Firm – BioForm
Facial Aesthetics Line To Help Mentor Keep Up With Medicis/Inamed
Facial Aesthetics Line To Help Mentor Keep Up With Medicis/Inamed
Aventis HIV Dermal Filler Approval Precedes Broader Cosmetic Trial
Collagen Implant PMA “Approvable” Letter Facilitates 2004 Launch – Artes
Advertisement
UsernamePublicRestriction

Register

MT022887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel